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Background: A useful heterologous production system is required to obtain sufficient amounts of recombinant
therapeutic proteins, which are often necessary for chemical characterization and engineering studies on the
development of molecules with improved properties. Human Fas ligand extracellular domain (hFasLECD) is an agonistic
death ligand protein that has potential applications for medical purposes. Site-specific chemical modifications can provide
a powerful means for the development of engineered proteins with beneficial functions. This study aimed to enhance
the yield of hFasLECD using a Pichia pastoris secretory expression system suitable for efficient production on a small
laboratory scale, and further to provide procedures for its site-specific chemical modification without impairing the
biological functions based on the developed production system.
Results: A convenient cultivation system using a disposable plastic bag provided a three-fold increase in purification yield
of tag-free hFasLECD as compared with the conventional system using a baffled glass flask. The system was further
applied to the production of a mutant, which contains an additional reactive cysteine residue in the N-terminal
tag-sequence region. Site-specific conjugations and cross-linking without impairing biological functions were achieved by
reaction of the mutant hFasLECD with single maleimide group containing compounds and a linear polyethylene glycol
derivative containing two maleimide groups at either end, respectively. All purified tag-free and chemically modified
hFasLECDs showed an evident receptor binding activity in co-immunoprecipitation experiments mediated by wild-type
and N-glycosylation site deficient mutant human Fas receptor extracellular domain derivatives. An N-Ethylmaleimide
conjugated hFasLECD derivative demonstrated a significant cytotoxic activity against human HT-29 colorectal cancer cells.
Conclusions: A new, efficient cultivation system for enhanced secretory production of hFasLECD using P. pastoris and an
effective strategy for site-specific chemical modifications of hFasLECD were devised. The results obtained constitute the
basis for biomedical applications including developments of novel therapeutic proteins and diagnostic tools targeted to
related diseases and their biomarkers.
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Abnormal apoptosis can cause many serious diseases,
such as cancers and rheumatoid arthritis, in the human
body [1]. Therefore, it has been assumed that the suc-
cessful artificial control of apoptotic processes will play a
substantial role in therapeutic interventions of these dis-
eases [2,3]. Human Fas ligand is a major death ligand
protein, which triggers the execution of cellular apop-
tosis via extrinsic pathway by specific binding of its
extracellular domain to that of an agonistic molecule,
human Fas receptor [4]. Heterologous expression is an
important means to fulfill the requirements for obtaining
sufficient amounts of therapeutic human proteins. De-
veloping an efficient production system is often neces-
sary not only for direct utilization as practical medicines,
but also for chemical characterization and engineering
studies [5,6]. Accordingly, functional recombinant wild-
type human Fas ligand extracellular domain (hFasLECD)
and its derivatives have been produced in heterologous
systems using several kinds of expression hosts including
Escherichia coli [7], Pichia pastoris [8-10] and Dictyoste-
lium discoideum [7].
Chemical modification, represented by pegylation, is a
powerful method for the development of engineered
proteins with beneficial functions, which include pro-
longed therapeutic activity in circulating blood, by add-
ing specific chemical properties into the target protein
molecules [11]. It may be also useful for the structural
characterization of interesting biological functions in na-
tive proteins. However, non-specific chemical modifica-
tions of protein molecules can interfere with the
expression of their intrinsic therapeutic properties either
by direct chemical transformation or by physical cover-
age of the critical functional groups. Site-specificity in
the modification can contribute to the enhancement of
useful functions and avoid unwanted effects of chemical
modifications. In this connection, we have conducted
several site-specific chemical modification studies with
human lysozyme for the purpose of both the alteration
of substrate specificity [12] and the clarification of the
origin of carbohydrate recognition specificity [13].
The extracellular domain of human Fas ligand locates
at the carboxyl-terminal region [amino acid residues (aa)
103-281] of whole molecule consisting of 281 aa, and in-
dependently exists as trimeric subunits without the help
of other parts of the molecule under physiological condi-
tions [4]. This domain contains three N-glycosylation
sites (Asn 184, Asn 250 and Asn 260) and two cysteine
residues (Cys 202 and Cys 233) forming a disulfide-
bridge. In previous studies, we developed a secretory
production system of recombinant hFasLECD using P.
pastoris as the expression host, and reported that both
the addition of N-terminal FLAG®-(Gly)5 tag sequence
[9] and the deletion of the non-essential region intrimerization (aa 103-138) [10] significantly increased
the secretion level of the products. We also showed that
two asparagine residues (Asn 184 and Asn 250) could be
mutated to glutamine residues without serious reduction
of the secretion level [9], and that the remaining hetero-
geneous N-glycan chains attached to Asn 260 in the N-
terminal FLAG®-(Gly)5 tagged double N-glycosylation
sites mutant could be trimmed to homogeneous N-acetyl
glucosamine residues without impairing the binding ac-
tivity [10] toward a recombinant human Fas receptor
extracellular domain (hFasRECD) derivative produced in
silkworm larvae [14,15].
In this report, a marked increase in the production
yield of tag-free hFasLECD achieved by the utilization of
a disposable plastic bag as the cultivation vessel is de-
scribed. This system was further applied to the secretory
production of a mutant, which has an additional reactive
cysteine residue within the above mentioned N-terminal
FLAG®-(Gly)5 tag sequence. The details of site-specific
chemical modifications of this mutant with maleimide
group containing compounds as well as the characteriza-
tions of the purified reaction products concerning bind-
ing activity toward hFasRECD and cytotoxic activity
against a cancer cell line will be presented.
Results
Enhanced yield of tag-free hFasLECD using disposable
culture-bag
Figure 1 summarizes the system used for the secretory pro-
duction of recombinant hFasLECDs in this study. As shown
in Figure 1a, the gene organization of the expression unit
was essentially the same as in the previous study [10].
Figure 1b illustrates the cultivation system using a plastic
culture-bag schematically. The necessary air for the growth
of P. pastoris transformant cells was supplied forcibly with
a diaphragm-type vacuum pump. The culture-bag on a
stainless-steel holder was rotated in a thermostatic air incu-
bator gently (80-85 rpm) during the cultivation period in
order to avoid sedimentation of the P. pastoris cells. The di-
mensions of the culture bag and the air ventilation speed
were 190 mm × 190 mm × 190 mm and 2.5 liter/min, re-
spectively. In Table 1, the purification course of tag-free
hFasLECD (Figure 1a) produced using the culture-bag sys-
tem and its N-glycan trimmed derivative is presented. The
purification of tag-free hFasLECD was performed through
two rounds of cation-exchange chromatography (Figure 2a).
Starting from 2300 ml of the recovered supernatant after
96 h cultivation, the final 29.4 mg yield of highly purified
tag-free hFasLECD sample (Figure 2c, solid line and
Figure 2d, lane a) was obtained. This purification yield
(12.8 mg per liter) corresponded to a three-fold increase as
compared with the previously reported purification yield
(4.2 mg per liter) concerning a sample of the same quality,
which was obtained from a total of 4000 ml culture
-Prepro Tag hFasLECD (139-281, N184Q, N250Q)AOX-1 P AOX-1 TT
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Figure 1 Production of recombinant hFasLECDs in this study. a) Gene structure of expression unit and variations in N-terminal tag
sequences. AOX-1 P, P. pastoris alcohol oxidase 1 promoter region; α-Prepro, Saccharomyces cerevisiae α-factor secretion-signal sequence; Tag, tag
sequence; hFasLECD (139-281, N184Q, N250Q), human Fas ligand extracellular domain containing deletion mutation from residue 103 to 138 and
double substitution mutations (N184Q and N250Q); AOX-1 TT, P. pastoris alcohol oxidase 1 transcription termination region. b) Schematic
presentation of P. pastoris cultivation system using disposable plastic bag.
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vation using a 3000 ml volume of glass baffled culture-flask
as reported previously [14].
As demonstrated in the previous study concerning
FLAG®-(Gly)5 tagged sample [10], the remaining N-glycans
in tag-free hFasLECD sample in this study could also be
trimmed with an Endo H-type glycosidase, Endo Hf
(Figure 2d, lane b). In Figure 2b and Figure 2c, the 3rd
cation-exchange chromatography profile of the sample after
the digestion with Endo Hf and the size-exclusion chroma-
tography profile of the cation-exchange chromatography
fractionated sample are shown, respectively. The sample-






Culture supernatant 2300 N. D.*1
1st Ultrafiltration plus buffer exchange 166 3320
1st Cation-exchange chromatography and
2nd ultrafiltration plus buffer exchange
10.5 54.2
2nd Cation-exchange chromatography 196*2 29.4*2
Endo Hf treatment, Con A-column frac-
tionation and 3rd Cation-exchange
chromatography
43*3 10.5*3
*1Not determined. *2Final N-glycan untrimmed product. *3Final N-glycan
trimmed product.was substantially delayed after Endo Hf digestion
(Figure 2c), which showed the effect of N-glycan trimming
on the molecular weight of tag-free hFasLECD. Figure 2d
summarizes the purification course during the N-glycan
trimming using sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) analysis (lanes a-d).
Receptor-mediated co-immunoprecipitation using wild-
type hFasRECD-T-Fc and Protein A-agarose beads was
used for the evaluation of the binding activity of the puri-
fied hFasLECD samples toward hFasRECD. In this study,
the binding activity of the samples was also examined using
a mutant hFasRECD-T-Fc, which contains double amino
acid residue substitutions (N102Q and N120Q) to remove
all possible N-glycosylation sites in the hFasRECD part
(Figure 3). In contrast to the presence of several discrete
bands in the final purified sample of isolated wild-type
hFasRECD part [15], this mutant gave a single band after
cleavage with bovine thrombin due to the lack of heterol-
ogous N-glycosylation (Figure 3, lane e). Both N-glycan un-
trimmed and trimmed tag-free hFasLECD samples
presented clear binding activity against either wild-type
hFasRECD-T-Fc or the N-glycan deficient mutant
(Figure 4a, lane b; Figure 4b, lanes a and b; Figure 2d, lanes
e and f).
Secretory expression of NFG1CG4-tagged hFasLECD
Based on promising results from the production of tag-






























































































Figure 2 Purification of N-glycan untrimmed and trimmed tag-free hFasLECDs. a) Elution profile of N-glycan untrimmed tag-free hFasLECD
sample (pre-purified by 1st Hi-Trap S cation-exchange chromatography) in 2nd cation-exchange chromatography. Used column: Resource S 6 ml.
The region shown in underbar was collected and used for characterization in c). NaCl concentration under principal peak eluting condition is
described. b) Elution profile of N-glycan trimmed tag-free hFasLECD sample in 3rd cation-exchange chromatography. Used column: Mono S 1 ml.
The region shown in underbar was collected and used for characterization in c). NaCl concentration under principal peak eluting condition is
described. c) Elution profiles of fractionated products in size-exclusion chromatography. Solid line: N-glycan untrimmed tag-free hFasLECD.
Dashed line: N-glycan trimmed tag-free hFasLECD. Used column: Superdex 200 10/300 GL. Elution buffer: 50 mM sodium acetate plus 150 mM
NaCl (pH 5.6). Flow rate: 0.5 ml/min. The peak retention time of each sample is described. Vertical arrows indicate the elution positions of
molecular-weight size-markers [Ald, aldolase (158 kDa); Ova, ovalbumin (44 kDa); Rna, ribonuclease A (13.7 kDa) under the same conditions.
d) SDS-PAGE analysis of purification course during N-glycan trimming with Endo Hf glycosidase and receptor-mediated co-immunoprecipitation
using wild type and mutant hFasRECD-T-Fcs. Lanes: a, N-glycan untrimmed tag-free hFasLECD; b, after Endo Hf digestion; c, after Con A column
fractionation; d, after Mono S column fractionation; e, co-immunoprecipitated materials using wild-type hFasRECD-T-Fc [15]; f, co-immunoprecipitated
materials using hFasRECD-T-Fc (N102Q, N120Q) mutant; M, Molecular-weight markers. “+CHO” and “ΔCHO” indicate the migration positions of
N-glycan untrimmed and N-glycan trimmed tag-free hFasLECD, respectively.
Muraki BMC Biotechnology 2014, 14:19 Page 4 of 16
http://www.biomedcentral.com/1472-6750/14/19(Figure 1a), which should have an additional reactive cyst-
eine residue per subunit of the trimeric molecule within
the (Gly)5 region in N-terminal FLAG®-(Gly)5 tagged hFa-
sLECD (NFG5-hFasLECD) (Figure 1a), was examined for
the applicability of the system using a disposable culture-
bag. In Figure 5a, a comparison of the secretion level of
NFG1CG4-hFasLECD between the cultivation system
using the baffled glass flask and that using the disposable
plastic bag is shown. As seen from the densities of the cor-
responding bands in SDS-PAGE analysis, the secretion
level was significantly improved in the culture-bag system
as compared with the baffled culture-flask system at all
sampling times of every 24 h interval within the 96 hcultivation (Figure 5a). The subunits composing secreted
NFG1CG4-hFasLECD trimers mainly existed as a couple
of forms, monomer and dimer, under disulfide-bridge
non-reducing conditions (Figure 5b, lane b). Both forms of
NFG1CG4-hFasLECD subunits in the culture supernatant
were involved in the specific binding toward wild-type
hFasRECD-T-Fc protein (Figure 5c, lane a). The possible
inter-subunit disulfide bond formed from the cysteine res-
idues in the dimeric subunits of NFG1CG4-hFasLECD
was easily cleaved with 2-mercaptoethanol contained in
the reducing sample loading buffer, and single major band
of the reduced sample appeared at the position of mono-
meric form in SDS-PAGE analysis (Figure 5b, lane a).















M   d e
Figure 3 SDS-PAGE analysis of digestion of hFasRECD-T-Fc (N102Q, N120Q) mutant with thrombin and purification of hFasRECD part.
Protein G-agarose column purified hFasRECD-T-Fc (N102Q, N120Q) mutant (470 μg) was digested with bovine thrombin (47 U) in 50 mM Tris-HCl
(pH 7.5) at 20°C, and the liberated mutant hFasRECD part in the reaction mixture was further purified as described previously [15]. Lanes: M,
molecular-weight size markers; a, before digestion; b and c, after digestion (b, 2 h; c, 4 h); d, after removal of Fc fragment by Protein G-agarose
column; e, after fractionation by cation-exchange chromatography. Used column: Resource S 1 ml.
Muraki BMC Biotechnology 2014, 14:19 Page 5 of 16
http://www.biomedcentral.com/1472-6750/14/19Chemical modification of NFG1CG4-hFasLECD with single
maleimide group containing compounds
The secreted NFG1CG4-hFasLECD was first partially
purified using the same cation-exchange chromatog-
raphy as described for tag-free hFasLECD, and then
treated with moderate concentration of Tris-(2-carbox-
yethyl)phosphine (TCEP) under neutral pH at room
temperature. This TCEP reduced product was immedi-



















M    a   b   c   d   e b)
Figure 4 SDS-PAGE analysis of hFasRECD-T-Fc mediated co-immunop
using wild-type hFasRECD-T-Fc [15]. Lanes: M, molecular-weight size-marke
adduct of NFG1CG4-hFasLECD, d, SUNBRIGHT® ME-050MA adduct of NFG1
were derived from wild-type hFasRECD-T-Fc sample. b) Comparison betwe
(N102Q, N120Q) mutant (lanes b, d and f). Lanes: M, molecular-weight size-
of NFG1CG4-hFasLECD; e and f, SUNBRIGHT® ME-050MA adduct of NFG1CG
hFasRECD-T-Fc samples.with two kinds of single maleimide-group containing
compounds, i. e. N-Ethylmaleimide and SUNBRIGHT®
ME-050MA. SUNBRIGHT® ME-050MA is a mono-
functional linear methoxy polyethylene glycol (PEG),
which has the molecular-weight of approximately 5 kDa
and contains an active maleimide group at one end
(Figure 6a). In Figure 6b, SDS-PAGE analysis of the re-
action mixtures at each individual step is shown. After










M   a   b    c    d   e   f
recipitation of the purified hFasLECDs. a) Co-immunoprecipitation
rs; a, NFG5-hFasLECD [10]; b, tag-free hFasLECD; c, N-Ethylmaleimide
CG4-hFasLECD; e, buffer alone. The bands in “FasR-Fc” labeled region
en wild-type hFasRECD-T-Fc (lanes a, c and e) and hFasRECD-T-Fc
markers; a and b, tag-free hFasLECD; c and d, N-Ethylmaleimide adduct
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Figure 5 SDS-PAGE analysis of secretory expression of NFG1CG4-hFasLECD. a) Comparison of the expression level using glass baffled-flask
with that using plastic culture-bag. Lanes: M, molecular-weight size-markers; a and b, at 0 h; c and d, at 24 h; e and f, at 48 h; g and h, at 72 h;
i and j, at 96 h. Five μl each samples of culture supernatants either from 500 ml scale culture in 3000 ml baffled flask (lanes a, c, e, g and i) or
2500 ml scale culture in 5000 ml disposable plastic bag (lanes b, d, f, h and j) were applied to each lane. Upper and lower arrows indicate the
migration positions of dimeric and monomeric subunits of NFG1CG4-hFasLECD, respectively. b) SDS-PAGE analysis of disulfide bond reduction in
partially purified NFG1CG4-hFasLECD. Main peak fraction of the P. pastoris culture supernatant (29.5°C, 96 h) in 1st cation-exchange column
chromatography was concentrated and treated with SDS-PAGE sample buffers with / without 2-mercaptoethanol. Lanes: M, molecular-weight size
markers; a, with 2-mercaptoethanol; b, without 2-mercaptoethanol. Upper and lower arrows indicate the same as in a). c) Co-immunoprecipitation
of the secreted product with wild-type hFasRECD-T-Fc. Lanes: M, molecular-weight size-markers; a, 5 μl culture supernatant of 40-fold concentrated
NFG1CG4-hFasLECD from 500 ml scale culture in 3000 ml baffled flask at 96 h; b, purified NFG5-hFasLECD [10] (5 μg); c, buffer alone. Upper and lower
arrows indicate the same as in a). The bands in “FasR-Fc” labeled region were derived from wild-type hFasRECD-T-Fc sample.













M   a  b   c d e  f b)
Figure 6 Reaction of NFG1CG4-hFasLECD with N-Ethylmaleimide/
SUNBRIGHT® ME-050MA. a) Chemical structures of N-Ethylmaleimide
and SUNBRIGHT® ME-050MA. b) SDS-PAGE analysis of the reaction
mixtures at each step. Lanes: M, molecular-weight size-markers; a, before
reaction; b, after reaction with TCEP; c, PD-10 column “Elution fraction”;
d, PD-10 column “Wash fraction”; e, after reaction with N-Ethylmaleimide
followed by quenching with L-Cysteine hydrochloride; f, after reaction
with SUNBRIGHT® ME-050MA followed by quenching with L-Cysteine
hydrochloride. Upper, middle and lower arrows indicate the migration
positions of disulfide-bridged subunits, SUNBRIGHT® ME-050MA adduct
and non-conjugated subunit/N-Ethylmaleimide adduct of
NFG1CG4-hFasLECD, respectively.
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the possible inter-subunit disulfide bond was completely
cleaved (lane b). This disulfide bond was slightly regen-
erated during the desalting step to remove excess
amount of TCEP (lane c). However, the original inter-
subunit disulfide bond was not observed in the reaction
mixture with an excess amount of single maleimide-
group containing compounds (lanes e and f).
The purification of the NFG1CG4-hFasLECD modified
with single maleimide-group containing compounds was
performed by cation-exchange column chromatography
(Figure 7a, center and right panels). The less sharp peak
following the main peak observed in the sample before
the conjugation reaction (Figure 7a, left panel) virtually
disappeared from the sample after modifications. The
sodium chloride (NaCl) concentrations required for elu-
tion of the chemically modified products depended on
the molecular structure of the maleimide reagent. The
main peak of N-Ethylmaleimide conjugated NFG1CG4-
hFasLECD was eluted under almost the same NaCl con-
centration (8.0 mM) as that for the main peak of the
sample before the conjugation reaction (8.1 mM). The
main peak of SUNBRIGHT® ME-050MA conjugated
NFG1CG4-hFasLECD was eluted under significantly
lower NaCl concentration (6.3 mM), suggesting weaker
binding to a negatively charged column carrier due to
the reduced ionic interactions caused by the possible






























































































35.60 min (13.7 kDa)
30.22 min (44 kDa)
25.04 min (158 kDa)
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Figure 7 Purification of NFG1CG4-hFasLECD conjugated with N-Ethylmaleimide/SUNBRIGHT® ME-050MA. a) Elution profiles in cation-exchange
chromatography. Used column: Resource S 1 ml. Panels: left, before reaction (non-reduced); center, after reaction with N-Ethylmaleimide and quenching;
right, after reaction with SUNBRIGHT® ME-050MA and quenching. The fractions shown in underbars were collected as the final products. NaCl
concentrations under each principal peak eluting condition are described. b) Elution profiles of fractionated products in size-exclusion chromatography.
Used column: Superdex 200 10/300 GL. Elution buffer: 50 mM sodium acetate plus 150 mM NaCl (pH 5.6). Flow rate: 0.5 ml/min. Panels: left,
molecular-weight standards mixture (A, Aldolase; B, Ovalbumin; C, Ribonuclease A); center, N-Ethylmaleimide modified product; right, SUNBRIGHT®
ME-050MA modified product. Retention times of each peak are described. c) SDS-PAGE analysis of fractionated products. Lanes: M, molecular-weight
size-markers; a, tag-free hFasLECD (0.15 μg); b, N-Ethylmaleimide adduct of NFG1CG4-hFasLECD (0.15 μg); c, SUNBRIGHT® ME-050MA adduct of
NFG1CG4-hFasLECD (0.15 μg).
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shape of each modified product, the fractionated sam-
ples in the above cation-exchange chromatography were
subjected to analysis using a size-exclusion chromatog-
raphy (Figure 7b). Either sample presented a symmetrical
single peak, suggesting the uniformity of molecular-weight
of the fractionated products (Figure 7b, center and right
panels). The peak retention time of the N-Ethylmaleimide
conjugated sample (28.78 min) was between the size-markers of 44 kDa (30.22 min) and 158 kDa (25.04 min)
(Figure 7b, left panel), and was nearly the same as ob-
served for tag-free hFasLECD (29.55 min) under the iden-
tical elution condition using the same chromatography
column (Figure 2c, solid line). This indicated that no sig-
nificant change in the molecular conformation occurred
to hFasLECD by the conjugation of N-Ethylmaleimide.
On the other hand, SUNBRIGHT® ME-050MA conju-
gated sample eluted markedly early (22.26 min) and the
Muraki BMC Biotechnology 2014, 14:19 Page 8 of 16
http://www.biomedcentral.com/1472-6750/14/19peak retention time was even significantly earlier than the
158 kDa size-marker (25.04 min). This suggested that the
PEG moieties attached to the N-terminal tag sequence re-
gion of NFG1CG4-hFasLECD had a much more extended
conformation to behave as a molecule with virtually bigger
molecular weight, which rendered the retention time
markedly earlier than the expected value from its actual
calculated molecular-weight (ca. 70 kDa as the triply
modified product).
Figure 7c shows the SDS-PAGE analysis of the fraction-
ated samples. As shown in lane b, the N-Ethylmaleimide
conjugated NFG1CG4-hFasLECD sample exhibited a single
band at the position of approximately 21 kDa. On the
other hand, the SUNBRIGHT® ME-050MA conjugated
NFG1CG4-hFasLECD sample exhibited two bands, which
consisted of one major thick band migrated at approxi-
mately 30 kDa and another minor faint band at 21 kDa
(Figure 7c, lane c). This result suggested that greatest por-
tions of free cysteine residues in the NFG1CG4-hFasLECD
sample were conjugated with SUNBRIGHT® ME-050MA
moieties. Table 2 summarizes the purification course of
NFG1CG4-hFasLECD conjugated with the single malei-
mide group containing compounds. Starting from 2500 ml
of the culture supernatant, 24.5 mg and 16.5 mg of the
purified products were recovered with respect to the N-
Ethylmaleimide adduct and the SUNBRIGHT® ME-050MA
adduct, respectively.
The purified samples conjugated with single maleimide
group containing compounds exhibited comparable bind-
ing activity to that of NFG5-hFasLECD toward wild type
hFasRECD-T-Fc (Figure 4a, lanes a, c and d). Both bands
in the SUNBRIGHT® ME-050MA conjugated sample were
found in the materials co-immunoprecipitated with wild-
type hFasRECD-T-Fc protein. Therefore, the minor band
was considered to be derived from a small fraction of the
functional trimeric product containing the subunit com-
ponent with the remaining non-conjugated cysteine
residue. The comparison of the data using wild-type
hFasRECD-T-Fc with that of the N-glycan deficient
hFasRECD-T-Fc mutant revealed that the binding activityTable 2 Purification course of NFG1CG4-hFasLECD






Culture supernatant 2500 N. D.*1
1st Ultrafiltration plus buffer-exchange 140 3024
1st Cation-exchange chromatography and
2nd ultrafiltration plus buffer-exchange
7.0 69.4
After chemical modification reaction and
2nd cation-exchange chromatography*2
100*3 108*4 24.5*3 16.5*4
*1Not determined. *2Normalized to the values starting from initial sample
volume (2500 ml). *3Final N-Ethylmaleimide conjugated product. *4Final
SUNBRIGHT® ME-050-MA conjugated product.toward this mutant was essentially maintained with all
examined hFasLECD samples (Figure 4b), however the
SUNBRIGHT® ME-050MA conjugated sample had a re-
duced binding strength toward the mutant hFasRECD-T-
Fc than the wild-type protein judging from the evident but
weaker density of the bands of the co-immunoprecipitated
materials (Figure 4b, lanes e and f).
Cross-linking of NFG1CG4-hFasLECD with two maleimide-
groups containing polyethylene glycol
Partially purified NFG1CG4-hFasLECD reduced with
moderated concentration of TCEP under neutral pH at
room temperature was also examined for cross-linking
with two maleimide groups containing compound,
SUNBRIGHT® DE-100MA. SUNBRIGHT® DE-100MA is
a homo-bifunctional linear PEG with the molecular-
weight of approximately 10 kDa, which has two malei-
mide groups at either end of the molecule (Figure 8a). In
Figure 8b, an elution profile of the reaction mixture after
the cross-linking reaction on a size-exclusion chroma-
tography column and SDS-PAGE analysis of the frac-
tionated peaks in the size-exclusion chromatography are
displayed. Peaks, I, II and III contained the cross-linked
materials. The band with the highest molecular-weight
between molecular size-markers of 66.3 kDa and
97.4 kDa found in the peak I sample (Figure 8b, right
panel, lane a) was regarded to correspond to the major
impurity protein found in the sample before the cross-
linking reaction (Figure 6b, lane c). From the molecular-
weight of the bands, the upper arrowed band and lower
arrowed band found in peaks I, II and III (Figure 8b,
right panel, lanes a, b and c) were considered to be
two NFG1CG4-hFasLECD subunits cross-linked by
one SUNBRIGHT® DE-100MA molecule and one
NFG1CG4-hFasLECD subunit conjugated with one
SUNBRIGHT® DE-100MA molecule, respectively. The
purification yields of the chemically modified products
contained in peaks II and III were 7.6 mg and 12.0 mg,
respectively, which were obtained from 2500 ml of the
culture supernatant of NFG1CG4-hFasLECD.
The samples fractionated as peaks II and III were inde-
pendently re-chromatographed on the same column
again (Figure 8c, left and center panels). Both peaks held
approximately the same original retention time, suggest-
ing that the product in peak II was not just a transient
aggregation of the product in peak III. The same
amounts of purified proteins were subjected to SDS-
PAGE analysis (Figure 8c, right panel). This revealed
that peak II and peak III contained essentially the same
subunit components with identical compositions. Mate-
rials in peak II were considered as an additional associ-
ated product of materials in peak III, which were
composed of more highly cross-linked NFG1CG4-
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Figure 8 Chemical modification of NFG1CG4-hFasLECD with SUNBRIGHT® DE-100MA. a) Chemical structure of SUNBRIGHT® DE-100MA.
b) Fractionation of the reaction mixture using size-exclusion chromatography. Used column: Superdex 200 10/300 GL. Elution buffer: 50 mM
sodium acetate plus 150 mM NaCl (pH 5.7). Flow rate: 0.5 ml/min. Panels: left, elution profile; right, SDS-PAGE analysis of each peak fraction.
Retention times of each peak are described (left panel). The fractions shown in underbars were collected as the final products. Lanes: a, peak I; b,
peak II; c, peak III; d, peak IV (right panel). The protein bands composed only of the NFG1CG4-hFasLECD subunits conjugated with SUNBRIGHT®
DE-100MA are arrowed. c) Characterization of the fractionated products. Panels: left and center, elution profiles of peak II (left) and peak III
(center). Retention times of each peak are described. Right panel, SDS-PAGE analysis. Lanes: M, molecular-weight size-markers; a, peak II fraction
(0.3 μg); b, peak III fraction (0.3 μg).
Muraki BMC Biotechnology 2014, 14:19 Page 9 of 16
http://www.biomedcentral.com/1472-6750/14/19found in the precipitated samples obtained in the
receptor-mediated co-immunoprecipitaion experiments
using either wild-type or the mutant hFasRECD-T-Fc
(Figure 9), which suggested that the cross-linked prod-
ucts in peaks II and III retained the binding activity to-
ward hFasRECD.
Cytotoxic activity of chemically modified NFG1CG4-
hFasLECD
In order to examine the cytotoxic activity of NFG1CG4-
hFasLECD containing site-specific modification with a
maleimide compound, the cell viability of a human colorec-
tal adenocarcinoma HT-29 cell line was evaluated using
3-(4, 5 Dimethylthiazol-2-yl 2, 5-diphenyl-tetrazoliumbromide (MTT) assay. The susceptibility enhancement in
apoptosis induction by pretreatment with interferon-γ
concerning this cell line [16] was not applied here.
Figure 10a shows the morphologic change of HT-29 cells
induced by treatment with N-Ethylmaleimide conjugated
NFG1CG4-hFasLECD, indicating the occurrence of apop-
tosis. A number of apparently dark and shrank cells sug-
gesting the occurrence of apoptosis, which were not
present in the sample at 72 h treatment by buffer alone
(lower), were observed in the micrograph of the sample at
72 h treatment by 100 ng/ml of N-Ethylmaleimide conju-
gated NFG1CG4-hFasLECD (upper). In Figure 10b, the
cytotoxic effect of the purified N-Ethylmaleimide con-
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Figure 9 SDS-PAGE analysis of hFasRECD-T-Fc mediated co-
immunoprecipitation of the fractionated hFasLECDs cross-
linked with SUNBRIGHT® DE-100MA. Either wild-type hFasRECD-T-
Fc (lanes a and c) or hFasRECD-T-Fc (N102Q, N120Q) mutant (lanes b
and d) was used for the experiment. Lanes: M, molecular-weight size
markers; a and b, peak II (co-immunoprecipitated sample); c and d,
peak III (co-immunoprecipitated sample); e, peak II (fractionated
sample, 0.3 μg); f, peak III (fractionated sample, 0.3 μg). The
components in the peaks II and III are arrowed.
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The Fas ligand sample exhibited significant cell-death in-
ducing activity in a dose and time dependent manner in
the presence of the M2 antibody. The buffer alone sample
























Figure 10 Cytotoxic activity of N-Ethylmaleimide conjugated NFG1CG
Panels: upper, 72 h treatment with N-Ethylmaleimide conjugated NFG1CG4-h
sample. Either treatment was conducted in the presence of anti-FLAG® M2 an
Symbols: white bars, in the absence of the M2 antibody; gray bars, in the prese
condition was included as an error bar. *(p < 0.05) and **(p < 0.01) show compafter 72 h treatment under either condition, and the cell
viability (mean ± standard deviation) in the presence and
absence of the M2 antibody was 95.3 ± 1.4% and 103 ±
3.4% of control, respectively. The above results suggested
the induction of apoptosis via Fas ligation by N-Ethylma-
leimide conjugated NFG1CG4-hFasLECD was evident
only after cross-linking through the recognition of FLAG®
sequence existing in the NFG1CG4-tag by M2 antibody.
Discussion
Heterologous production systems of recombinant hu-
man Fas ligand extracellular domain have been devel-
oped using several expression hosts. It has been shown
that P. pastoris and D. discoideum were the most effi-
cient hosts in providing functional products by direct se-
cretion without the necessity of fusion with other
protein domains [6]. A methanol utilization plus strain,
P. pastoris GS115 (Mut+), has been used as the host in
the secretory production of this protein [8-10,14]. The
best purification yield of 24.3 mg/l was reported with
the NFG5-hFasLECD (aa 139-281) containing the muta-
tions of N184Q and N250Q [10]. However, the deletion
of NFG5 tag sequence in this mutant resulted in a large
reduction of the purification yield to 4.2 mg/l [14]. In
this study, it was shown that the purification yield of
tag-free hFasLECD could be increased 3-fold by altering
the cultivation vessel used in the production system
from glass baffled flask to disposable plastic bag. Good
aeration during cultivation in expression induction-
phase using methanol is a critical factor in the produc-
tion efficiency of the recombinant proteins in P. pastoris.
The cell density of another species of yeast, Saccharomy-
ces cerevisiae, was significantly increased in cultivation










4-hFasLECD against HT-29 cells. a) Effect on cell morphology.
FasLECD sample (100 ng/ml); lower, 72 h treatment with buffer alone
tibody (2 μg/ml). b) Effect of sample concentration and treatment time.
nce of the M2 antibody. Standard error of mean under each experimental
arisons with the control experiments using Student’s t-test.
Muraki BMC Biotechnology 2014, 14:19 Page 11 of 16
http://www.biomedcentral.com/1472-6750/14/19baffled flask (Y. Kawabata, personal communications). In
another experiment for the production of NFG1CG4-
hFasLECD in P. pastoris GS115 strain using 4000 ml
BMMY medium in a 10 liter volume plastic culture-bag
(CB-10; Fujimori Kogyo), an approximately 50% increase
in optical density at 600 nm was obtained compared
with the corresponding cultivation using 50 ml BMMY
medium in 500 ml triple side-baffled glass flask after
96 h cultivation (unpublished result). Therefore, the
main reason for the yield enhancement in this study
may be ascribed to better aeration by the forced air ven-
tilation using a diaphragm pump and increase of cell
density in the cultivation.
Single-use technologies using disposable apparatus in-
cluding plastic bags are currently evolving industrial
technologies, which have a number of merits in the pro-
duction of recombinant proteins, especially in the field
of bio-pharmaceutical manufacturing [17]. One of the
important areas of the application of single-use tech-
nologies is fermentation of microorganisms including P.
pastoris. In this study, it was demonstrated that the use
of a disposable plastic bag was also effective for the pur-
pose of enhancing the yield of recombinant proteins
aiming at the research of its site-specific modification
using P. pastoris as the producer. To date, remarkable
increases in the yield of recombinant proteins from
shake-flask systems have been achieved in many cases
by non-disposable system such as a jar fermenter, which
are mostly made of glass and stainless-steel [18]. This
study demonstrated that the alternative possibility of en-
hancing the yield using disposable plastic culture-bag
system, though the increased level was moderate as
compared with a reusable fermenter system operated
under optimized conditions. Alteration of the cultivation
vessel provided not only an increase in the purification
yield per unit volume of the culture supernatant but also
reduction of the number of vessels necessary for the
same total cultivation volume. Moreover, the plastic
culture-bag system requires neither any special ingredi-
ent in the medium nor expensive equipment for cultiva-
tion, making this system convenient compared with a
fermenter system, which requires special materials for
cultivation. The culture-bag system should be readily ap-
plicable to production of other recombinant proteins in
yeasts on a small laboratory scale.
The interactions between hFasLECD and hFasRECD con-
stitute a key signaling step in the initiation of apoptotic pro-
cesses via extrinsic pathway mediated by human Fas
receptor. Some aspects of the interactions have been char-
acterized through the site-directed mutagenesis studies
[19,20] and the three-dimensional structures produced by
in silico modeling [21,22]. Either tag-free hFasLECD con-
taining untrimmed or trimmed N-glycan exhibited virtually
identical binding activity toward mutant hFasRECD-T-Fclacking N-glycosylation site within the hFasRECD part with
the activity toward wild type hFasRECD-T-Fc, suggesting
N-glycosylation in both hFasLECD and hFasRECD is not a
prerequisite for protein – protein interactions between hFa-
sLECD and hFasRECD.
Site-specific chemical modifications provide a useful
method to obtain proteins with improved pharmaceut-
ical properties by enhancing in vivo biological efficacy. A
number of therapeutic proteins with site-specific modifi-
cations, especially pegylation, have been developed [23].
Suitable selection of the structural position for modifica-
tion is essential for effective derivation, while main-
taining the intrinsic biological functions of the target
proteins. The N-terminal region of NFG1CG4-hFasLECD
is thought to be located distant from the binding in-
terface to hFasRECD judging from a detailed three-
dimensional structure of the complex between hFasLECD
and a decoy receptor, DcR3 [24].
NFG5-hFasLECD (aa 139-281, N184Q, N250Q) is con-
sidered to contain a single disulfide bond between Cys
202 and Cys 233 within a structurally buried region by
analogy with the available three-dimensional structure of
hFasLECD [24]. However, it is known that TCEP can se-
lectively reduce solvent exposed disulfide bonds under
mild reaction conditions without affecting the structur-
ally buried one [25]. Therefore, the N-terminal tag se-
quence region in NFG5-hFasLECD [9] was chosen as
the introduction site of solvent accessible cysteine resi-
due for site-specific chemical modifications in this study.
A free cysteine residue is ideal for selective modifications
due to its unique reactive properties against many elec-
torophiles [25,26]. The maleimide group containing
compound is useful, since a variety of commercial com-
pounds including those for pegylation are readily avail-
able with reasonable prices. It was found that
NFG1CG4-tag sequence, FLAG®-GlyCys(Gly)4, effect-
ively worked as a new N-terminal tag for site-specific
chemical modifications, which provided an alternative to
existing methods for N-terminal conjugation using dif-
ferent tag sequences [27,28].
The N-Ethylmaleimide conjugated NFG1CG4-hFasLECD
exhibited a cell-death inducing activity against HT-29
cells, a human colorectal adenocarcinoma cell line. The
cytotoxic activity was significant only after cross-linking
by M2 antibody specific for FLAG®-tag as depicted with
the activity of a FLAG®-tagged trimeric hFasLECD against
Jurkat, Raji and HeLa cells [29]. This suggested that site-
specific chemical modifications via conjugation of the
cysteine residue in the N-terminal NFG1CG4-tag with
maleimide compounds were possible without losing the
intrinsic pro-apoptotic function of the sample produced in
P. pastoris [8]. This result constitutes the basis of develop-
ment of novel type cytotoxic therapeutic agents using site-
specific chemical modifications with targeting moieties
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[30,31]. This also showed that the two N-glycan chains at
Asn184 and Asn250 sites were not always essential for
exhibiting the cell-death inducing activity.
To our knowledge, this is the first report describing
preparations of functional hFasLECD samples with site-
specific chemical modifications. Human FasLECD works
as a pro-apoptotic receptor agonist by binding to hFas-
RECD on the plasma membrane of target cells. However,
it also binds to DcR3 with a similar affinity to hFasRECD
at the same time [32], which can be one of the possible
reasons leading to onset of diseases caused by excessive
cellular proliferation [33]. Overexpression of DcR3 decoy
receptor was found in several types of cancers and auto-
immune diseases [34]. Protein engineering studies in-
cluding the site-specific chemical modifications might
contribute to solve this problem by tuning the receptor
binding specificity of hFasLECD.
It has been shown that a hexameric, genetically fused
proteins containing two trimers of hFasLECD within the
assembled molecule via the association of ACRP30 colla-
gen domain region, displayed much higher killing activ-
ity than trimeric hFasLECD against several kinds of
tumor cells [29]. The site-specific cross-linking strategy
concerning hFasLECD demonstrated in this study might
also contribute to the development of such engineered
molecules with enhanced cell-killing activity.
Possible applications aimed at membrane bound forms
of human Fas receptor on the targeted cells include
in vivo / in vitro imaging of positive cells [35] by conju-
gations with either fluorescent dyes [36] or luminescent
proteins [37]. It is also known that soluble agonistic and
decoy receptor proteins concerning human Fas receptor
system are useful biomarkers in serum, urine and other
body fluids for early diagnosis [38], prognosis [39,40], re-
sponse to drug treatment [41] and mortality [42] of
many serious human diseases represented by cancers.
The mutant hFasLECD containing the reactive cysteine
residue conjugable to maleimide group containing com-
pounds should also become a powerful molecular agent
in developing devices for quantifying such disease spe-
cific biomarkers.
Conclusions
In the present study, a new, convenient and efficient
production system by P. pastoris using a disposable plas-
tic culture-bag was developed, which requires neither
special ingredients in the culture medium nor expensive
equipment such as a jar fermenter. Using this system,
the purification yield of tag-free hFasLECD increased
three-fold. This system was also applicable to the
secretory production of a mutant hFasLECD, which was
appropriate for the site-specific conjugations with malei-
mide group containing compounds. The enhanced yieldwill facilitate further chemical characterization studies
on hFasLECD. The conjugated hFasLECDs with malei-
mide group containing compounds at its N-terminal tag
sequence showed receptor binding and cell-death indu-
cing activities. The site-specific chemical modifications
of hFasLECD should contribute to development of novel
therapeutic agents as well as tools for diagnostic pur-
poses in the biomedical field.
Methods
Materials
Plasmid vectors, pNFG5-hFasLECD (aa 139-281) with
(N184Q, N250Q) double mutations and its tag-free ver-
sion were prepared as described in previous papers
[10,14]. The insertion mutation for the introduction of
the additional cysteine residue in NFG1CG4-hFasLECD
(Figure 1a) was conducted by in vitro mutagenesis of
NFG5-hFasLECD gene as a custom service by Takara-bio
Co. Pichia pastoris GS115 (Mut+) was used as the strain
for expression. Buffered glycerol complex medium (BMGY
medium) and buffered methanol complex medium (BMMY
medium) were prepared as described [9]. Triple side-
baffled culture flasks were purchased from Asahi Glass
Co., Ltd. Disposable plastic culture-bags (CB-5) and a
stainless-steel bag-holder (Bag-holder 10) were products
of Fujimori Kogyo Co., Ltd. NFG5-hFasLECD protein was
obtained as described previously [10]. Wild-type and
(N102Q, N120Q) mutant hFasRECD-T-Fc proteins were
obtained using baculovirus-silkworm expression system
[15]. The 10-20% gradient gels used for SDS-PAGE ana-
lysis and L-Cysteine hydrochloride monohydrate were
purchased from Wako Pure Chemical Ind., Ltd. Culture
filtration-devices and tangential flow filtration-devices
for concentration were obtained from Nihon Pall, Ltd.
Cation-exchange chromatography and size-exclusion chro-
matography were performed using columns and devices
from GE healthcare. BCA protein assay kit and TCEP
neutral pH solution were purchased from Thermo Fisher
Scientific Inc. SUNBRIGHT® ME-050MA: α-[3-(3-Malei-
mido-1-oxopropyl) amino]propyl-ω-methoxy, polyoxyethy-
lene (5 kDa fraction, 98.1%; average molecular weight,
5393; polydispersity, 1.02; maleimide group content,
95.0%) and SUNBRIGHT® DE-100MA: α-[3-(3-Malei-
mido-1-oxopropyl)amino]propyl-ω-[3-(3-Maleimido-1-oxo-
propyl)amino]propoxy, polyoxyethylene (10 kDa fraction,
96.0%; average molecular weight, 10644; polydispersity,
1.02; terminal activated rate, 83.9%) were obtained from
NOF Co. N-Ethylmaleimide and Phosphate buffer solu-
tion (pH 6.4) were from Nakarai Tesque. Immunopre-
cipitation kit (Protein A) was from Roche Diagnostics.
Other chemical reagents of analytical grade and devices
used for protein purification were as described [9].
Chemical structure of maleimide group was drawn using
Accelrys Draw 4.1.
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culture-flask
The experimental procedures used during the selection
of efficient single colonies of the recombinant P. pastoris
and those used for the secretory production of tag-free
hFasLECD in 500 ml scale culture of BMMY medium
(pH 6.2-6.5) using a 3000 ml baffled flask made of boro-
silicate glass were the same as described previously [15].
Cultivation was conducted at 29.5°C with a rotation of
300 rpm in a thermostatic air incubator (BR-32FL;
TAITEC).
Expression of tag-free and NFG1CG4-hFasLECDs using
disposable plastic culture-bag
The same BMMY medium for the above baffled culture-
flask was used in the cultivation of P. pastoris transfor-
mant using a disposable culture-bag made of polypropyl-
ene. The P. pastoris pre-culture was prepared by
cultivation in 500 ml BMGY medium (pH 6.2-6.5) at
29.5°C, 300 rpm overnight using 3000 ml triple side-
baffled glass flask. The pre-culture was centrifuged at
8000 rpm for 2 min at room temperature to give the seed
cell-pellets for the inoculation of 2500 ml BMMY medium
made of either autoclaved or filter-sterilized components
in 5000 ml volume of the disposable culture bag. The
cultivation was conducted at 29.5°C with a rotation of
80-85 rpm for 96 h in the same thermostatic air incubator
as described above. The induction of expression was made
by the addition of 0.5% methanol at 24 h intervals.
Purification of secreted products
The culture medium containing the secreted hFasLECDs
was centrifuged and the supernatant was sterilely filtered
with a double (0.8 μm and 0.2 μm) poly-ethersulfone
membrane. The filtrate was transferred to an ultrafiltra-
tion device equipped with a poly-ethersulfone membrane
for tangential flow filtration (Molecular-weight cut off:
10 kDa) to concentrate to approximately 100 ml. The
concentrated retentate was further buffer-exchanged
using 50 mM sodium acetate (pH 5.6). The buffer-
exchanged solution was then loaded on a Hi-Trap S
cation-exchange column (5 ml) equilibrated with 50 mM
sodium acetate buffer (pH 5.6). The recombinant protein
was eluted with either 500 mM NaCl (for tag-free hFa-
sLECD) or 300 mM NaCl (for NFG1CG4-hFasLECD).
The eluted samples were concentrated using an Amicon
Ultra-15 ultrafiltration device (10 kDa) to ca. 4 ml, and
further desalted with PD-10 column (8.3 ml) using
50 mM sodium acetate buffer (pH 5.6).
With respect to tag-free hFasLECD, the desalted solu-
tion was loaded on a Resource S cation-exchange col-
umn (6 ml) equilibrated with 50 mM sodium acetate
buffer (pH 5.6). The recombinant proteins were eluted
with a linear salt gradient from 50 to 450 mM NaCl in50 mM sodium acetate buffer (pH 5.2) at the flow rate
of 6 ml/min. The fractions containing the recombinant
hFasLECD were pooled as the final product. The protein
concentration of the samples at each purification step
was determined by a BCA protein assay kit using bovine
serum albumin as a standard. As for NFG1CG4-
hFasLECD, the protein concentration of the desalted so-
lution after the purification step with the Hi-Trap S 5 ml
column was determined to be 9.9 mg/ml, and was dir-
ectly used for the reaction with maleimide group con-
taining compounds.
Preparation of N-glycan trimmed tag-free hFasLECD
Purified sample of tag-free hFasLECD was concentrated
to 1.92 mg/ml with Amicon Ultra 15 (Molecular weight
cut-off: 10 kDa), and digested with Endo Hf (New
England Biolabs, Inc.). Twelve μl of 500 mM sodium cit-
rate buffer (pH 5.5) was added to 192 μg of tag-free hFa-
sLECD sample and then treated with 12000 U of Endo
Hf at 37°C, for 48 h. The N-glycan trimmed tag-free
hFasLECD in the reaction mixture was purified accord-
ing to essentially the same procedures as described for
NFG5-hFasLECD [10]. In brief, the above Endo Hf reac-
tion mixture was first subjected to Con A-agarose col-
umn to trap the N-glycan untrimmed tag-free
hFasLECD, and the flow-through fraction containing the
N-glycan trimmed tag-free hFasLECD was then further
fractionated by Mono S 1 ml column cation-exchange
chromatography using the elution with a linear salt gra-
dient from 50 to 550 mM NaCl in 50 mM sodium acet-
ate buffer (pH 5.6).
Reaction of NFG1CG4-hFasLECD with maleimide group
containing compounds
The reactions of NFG1CG4-hFasLECD sample with
single maleimide group containing compounds (N-Ethyl-
maleimide and SUNBRIGHT® ME-050MA) were con-
ducted as follows. An aliquot of the sample solution
(1.6 ml) containing 15.8 mg protein was mixed with
16 μl of 0.5 M Ethylenediaminetetraacetic acid sodium
salt (EDTA Na) solution (pH 8.0) and then treated with
64 μl of 0.5 M TCEP solution (neutral pH) for 1 h at
27°C. The reaction mixture was resolved by a PD-10
desalting column (8.3 ml) to remove excess amount of
TCEP using 25 mM phosphate buffer plus 2 mM EDTA
Na (pH 6.4) as the eluent. After the loading of the sam-
ple in a total volume of 2.5 ml into the column, 3.5 ml
of the buffer followed by another 2.5 ml of the buffer
was added to collect the flow-through. The former
3.5 ml and the latter 2.5 ml flow-through fractions were
named “Elution fraction” and “Wash fraction”, respect-
ively. Virtually, no reduced product was found in the
“Wash fraction” (Figure 6b, lane d). The “Elution frac-
tion” was divided into two 1.75 ml parts equally. Either
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in ethanol or 189 mg of solid SUNBRIGHT® ME-050MA
powder was added to each solution. After 15 min at
27°C, 33 μl of 1 M L-Cysteine hydrochloride solution in
water was added to each reaction mixture, and further
incubated at 27°C for 15 min in order to quench the ex-
cess maleimide groups.
The reaction of NFG1CG4-hFasLECD sample with
SUNBRIGHT® DE-100MA was performed as follows. An
aliquot of the sample solution (1.6 ml) containing
15.8 mg protein was first treated with TCEP in the same
way as described for the reaction with single maleimide
group containing compounds. Then, 100 μl of freshly
prepared SUNBRIGHT® DE-100MA solution (80 mg in
5 ml) in 25 mM phosphate buffer plus 2 mM EDTA Na
(pH 6.4) was added to the PD-10 column “Elution frac-
tion” (3.5 ml), and incubated for 1 h at 22°C. Seventy μl
of 1 MN-Ethylmaleimide solution in ethanol was added
to the reaction mixture and was incubated for 15 min at
22°C to cap the unreacted free cysteine residues in the
NFG1CG4-hFasLECD sample. After that, 69 μl of
1 M L-Cysteine hydrochloride was added and incubated
for a further 15 min at 22°C to quench the excess malei-
mide groups.
Purification of chemically modified NFG1CG4-hFasLECD
The final reaction mixtures concerning the chemical
modification of NFG1CG4-hFasLECD with single malei-
mide group containing compounds were buffer-exchanged
with 50 mM sodium acetate solution (pH 5.3) using PD-
10 desalting column (8.3 ml). This solution was loaded on
a Resource S cation-exchange column (1 ml) equilibrated
with the same buffer. The recombinant protein was re-
solved with a linear salt gradient from 0 to 250 mM NaCl
in 50 mM sodium acetate buffer (pH 5.3) at the flow rate
of 1 ml/min. The main peak fractions containing the
chemically modified NFG1CG4-hFasLECD were pooled,
and the product yield was quantified by BCA protein
assay.
As for the reaction product of NFG1CG4-hFasLECD
with SUNBRIGHT® DE-100MA, the final reaction mix-
ture was first desalted using PD-10 column (8.3 ml) and
then concentrated to ca. 1.0 ml with Amicon Ultra 8
ultrafiltration device (Molecular-weight cut off: 10 kDa).
An aliquot (230 μl) of the concentrated sample was re-
solved by a Superdex 200 10/30 GL size-exclusion col-
umn (diameter, 10 mm; length, 300 mm) using 50 mM
sodium acetate plus 150 mM NaCl (pH 5.6) elution buf-
fer at the flow rate of 0.5 ml/min. The samples of each
peak fraction were analysed by SDS-PAGE. The second
and the third peak fractions containing inter-molecularly
cross-linked NFG1CG4-hFasLECD products were pooled,
and the recovery yields were quantified by BCA protein
assay.Molecular-weight estimation using size-exclusion
chromatography
Molecular-weight of the purified samples was estimated
by a Superdex 200 10/30 GL size-exclusion column
(diameter, 10 mm; length, 300 mm) using the same elu-
tion conditions as described above. Fifty five μg each of
the untrimmed and N-glycan trimmed tag-free hFa-
sLECD, 35 μg each of the NFG1CG4-hFasLECD modi-
fied with single maleimide group containing compounds
(N-Ethylmaleimide and SUNBRIGHT® ME-050MA), or
230 μl each pooled fractions of the NFG1CG4-
hFasLECD cross-linked with SUNBRIGHT® DE-100MA
were subjected to chromatography. A mixture of
molecular-weight standard proteins (Aldolase, 158 kDa;
Ovalbumin, 44 kDa and Ribonuclease A, 13.7 kDa) was
used as size-markers.
Receptor-mediated co-immunoprecipitation of hFasLECD
Detection of the binding activity of hFasLECD samples to-
ward Fas receptor was performed by receptor-mediated lig-
and immunoprecipitation assay using hFasRECD-T-Fc
proteins and Protein A-agarose beads. A commercially
available immunoprecipitation kit was used for the assay.
The experimental procedures were the same as described
in the previous paper [10]. Purified NFG5-hFasLECD pro-
tein was employed as the authentic positive control sample.
Cell culture and cytotoxicity assay
Human colorectal adenocarcinoma cell line HT-29 cells
(catalog no. HTB-38) were purchased from ATCC, and
maintained in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma) supplemented with 10% fetal bovine
serum (Biowest), and 1 mM sodium pyruvate at 37°C in
a 95% humidified air-5% CO2 incubator. Cell passages
were carried at 80% confluence at a ratio of 1:3, using
trypsin EDTA (Sigma) to detach cells.
HT-29 cells were seeded at 2 × 104 cells/well in 100 μl
medium in 96 wells microplates (BD Falcon). Cells were
allowed to attach and grow for 24 h under 37°C, 95% hu-
midified air-5% CO2 incubation conditions before treat-
ment with Fas ligand samples. Serially diluted Fas ligand
samples (0.1, 1, 10, 100 and 1000 ng/ml) mixed with or
without anti-FLAG® M2 antibody (Sigma, 2 μg/ml) were in-
cubated for 48 h or 72 h in a final volume of 100 μl
medium. The control experiments and the vehicle experi-
ments consisted of medium only treatment and sample di-
lution buffer (50 mM sodium acetate plus 150 mM NaCl,
pH 5.6) in medium treatment, respectively. Either of them
was incubated with or without 2 μg/ml anti-FLAG® M2
antibody.
Cell viability was evaluated using MTT assay. Ten μl
of MTT (5 mg/ml in PBS) was added to each well at the
end of the treatment, and the plates were protected from
light and incubated overnight at 37°C in a 95%
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SDS solution was added to dissolve the formed forma-
zan, and the plates were incubated for extra 24 h under
the same conditions. Absorbance at 570 nm was re-
corded using Power Scan plate reader (Dainippon phar-
maceuticals). Cell viability was calculated as % of
control. A series of experiments were conducted in trip-
licate for each independent condition. Duplicate series
of experimental data (n = 6 in total) were used for statis-
tical evaluation of cell viability.
Abbreviations
hFasLECD: Human Fas ligand extracellular domain; hFasRECD: Human Fas
receptor extracellular domain; hFasRECD-T-Fc: A fusion protein composed of
human Fas receptor extracellular domain and human IgG1-Fc domain
containing a thrombin cleavage site within the fusion-region sequence;
aa: Amino acid residues; BMGY medium: Buffered glycerol complex medium;
BMMY medium: Buffered methanol complex medium; TCEP: Tris-(2-
carboxyethyl)phosphine; EDTA Na: Ethylenediaminetetraaceticacid sodium
salt; PEG: Polyethylene glycol; NaCl: Sodium chloride; SDS-PAGE: Sodium
dodecyl sulfate polyacrylamide gel-electrophoresis.
Competing interests
The author has applied to the Japan Patent Office for a patent relating to
the content of this paper.
Acknowledgements
This work was supported by a grant for operating expenses from the
Ministry of Economy, Trade and Industry, Japan. The author would like to
thank Mr. Y. Kawabata (Fujimori Kogyo Co. Ltd.) and Mr. J. Baba (Nihon Pall
Ltd.) for technical assistance with the devices used in this study. The cell
culture and cytotoxicity assay was performed as a custom service of
Research Institute of Biomolecule Metrology, Co. Ltd., Japan. The author
thanks to Drs. A. E. Omri and Y. Sugiyama for technical assistance and helpful
advice on cytotoxicity assay. Editorial assistance in the preparation of the
manuscript by Prof. C.S. Langham (School of Dentistry, Nihon University) is
also gratefully acknowledged.
Received: 25 June 2013 Accepted: 3 March 2014
Published: 11 March 2014
References
1. Nagata S: Apoptosis by death factor. Cell 1997, 88:355–365.
2. Ashkenazi A: Directing cancer cells to self-destruct with pro-apoptotic
receptor agonists. Nat Rev Drug Discov 2008, 7:1001–1012.
3. Vinay DS, Kwon BS: The tumor necrosis factor/TNF receptor superfamily:
therapeutic targets in autoimmune diseases. Clin Exp Immunol 2011,
164:145–157.
4. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S: Human Fas
ligand: gene structure, chromosomal location and species specificity.
Int Immunol 1994, 6:1567–1574.
5. Ferrer-Miralles N, Domingo-Espín J, Corchero JL, Vázquez E, Villaverde A:
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact
2009, 8:17.
6. Muraki M: Heterologous production of death ligands’ and death
receptors’ extracellular domains: structural features and efficient
systems. Protein Pept Lett 2012, 19:867–879.
7. Luo Z, Xu Z, Zhuo S, Jing K, Lu Y: Production, purification and cytotoxity
of soluble human Fas ligand expressed by Escherichia coli and
Dictyostelium discoideum. Biochem Engineer J 2012, 62:86–91.
8. Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S: Lethal effect of
recombinant human Fas ligand in mice pretreated with
Propionibacterium acnes. J Immunol 1997, 158:2303–2309.
9. Muraki M: Secretory expression of synthetic human Fas ligand
extracellular domain gene in Pichia pastoris: influences of tag addition
and N-glycosylation site deletion, and development of a purification
method. Protein Expr Purif 2006, 50:137–146.10. Muraki M: Improved secretion of human Fas ligand extracellular domain
by N-terminal part truncation in Pichia pastoris and preparation of the
N-linked carbohydrate chain trimmed derivative. Protein Expr Purif 2008,
60:205–213.
11. Harris JM, Chess RB: Effect of pegylation on pharmaceuticals. Nat Rev Drug
Discov 2003, 2:214–221.
12. Muraki M, Jigami Y, Harata K: Alteration of the substrate specificity of
human lysozyme by site-specific intermolecular cross-linking. FEBS Lett
1994, 355:271–274.
13. Muraki M, Harata K, Sugita N, Sato KI: Origin of carbohydrate recognition
specificity of human lysozyme revealed by affinity labeling.
Biochemistry 1996, 35:13562–13567.
14. Muraki M, Honda S: Efficient production of human Fas receptor extracellular
domain-human IgG1 heavy chain Fc domain fusion protein using
baculovirus/silkworm expression system. Protein Expr Purif 2010, 73:209–216.
15. Muraki M, Honda S: Improved isolation and purification of functional
human Fas receptor extracellular domain using baculovirus – silkworm
expression system. Protein Expr Purif 2011, 80:102–109.
16. Ebert EC, Groh V: Dissection of spontaneous cytotoxicity by human
intestinal intraepitherial lymphocytes: MIC on colon cancer triggers
NKG2D-mediated lysis through Fas ligand. Immunology 2008, 124:33–41.
17. Shukla AA, Gottschalk U: Single-use disposable technologies for
biopharmaceutical manufacturing. Trends Biotech 2013, 31:147–154.
18. Higgins DR, Cregg JM: Pichia Protocols, [Methods in Molecular Biology Vol.
103]. Totowa NJ: Humana Press; 1998.
19. Schneider P, Bodmer JL, Holler N, Mattmann C, Scuderi P, Terskikh A, Peitsch
MC, Tschopp J: Characterization of Fas (Apo-1, CD95)-Fas ligand
interaction. J Biol Chem 1997, 272:18827–18833.
20. Orlinick JR, Elkon KB, Chao MV: Separate domains of the human Fas
ligand dictate self-association and receptor binding. J Biol Chem 1997,
272:32221–32229.
21. Bajorath J: Identification of the ligand binding site in Fas (CD95) and
analysis of Fas-ligand interactions. Proteins 1999, 35:475–482.
22. Shatnyeva OM, Kubarenko AV, Weber CEM, Pappa A, Schwartz-Albiez R,
Weber ANR, Krammer PH, Lavrik IN: Modulation of the CD95-induced
apoptosis: the role of CD95 N-glycosylation. PLoS ONE 2011, 6:e19927.
23. Nett JH, Gomathinayagam S, Hamilton SR, Gong B, Davidson RC, Du M,
Hopkins D, Mitchell T, Mallem MR, Nylen A, Shaikh SS, Sharkley N, Barnard
GC, Copeland V, Liu L, Evers R, Li Y, Gray PM, Lingham RB, Visco D, Forrest
G, DeMartino J, Linden T, Potgieter TI, Wildt S, Stadheim TA, d’Anjou M, Li H,
Sethuraman N: Optimization of erythropoietin production with controlled
glycosylation-PEGylated erythropoietin produced in glycoengineered
Pichia pastoris. J Biotechnol 2012, 157:198–206.
24. Liu W, Ramagopal UA, Zhan C, Bonanno JB, Bhosle RC, Nathenson SG,
Almo SC; Atoms-to-Animals: The immune Function Network (IFN), New York
Structural Genomics Research Consortium (NYSGRC): Crystal Structure of
FASL and DcR3 complex. [http://pdbj.org/mine/summary/4msv]
25. Hermanson GT: Bioconjugate Techniques. 2nd edition. London: Academic
Press; 2008.
26. Chalker JM, Bernardes GJL, Davis BG: A “Tag-and-Modify” approach to
site-selective protein modification. Acc Chem Res 2011, 44:730–741.
27. Backer MV, Levashova Z, Levenson R, Blankenberg FG, Backer JM: Cysteine-
containing fusion tag for site-specific conjugation of therapeutic and
imaging agents to targeting proteins. Methods Mol Biol 2008, 494:275–294.
28. Cong Y, Pawlisz E, Bryant P, Balan S, Laurine E, Tommasi R, Singh R, Dubey
S, Peciak K, Bird M, Sivasanker A, Swierkosz J, Muroni M, Heidelberger S,
Farys M, Khayrzad F, Edwards J, Badescu G, Hodgson I, Heise C, Somavarapu
S, Liddell J, Powell K, Zloh M, Choi JW, Godwin A, Brocchini S: Site-specific
PEGylation at histidine tags. Bioconj Chem 2012, 23:248–263.
29. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon
F, Tinel A, Deperthes D, Calderara S, Schulthess T, Engel J, Schneider P,
Tschopp J: Two adjacent trimeric Fas ligands are required for Fas signaling
and formation of a death-inducing signaling complex. Mol Cell Biol 2003,
23:1428–1440.
30. Bremer E, Cate BT, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau
M, van de Loosdrecht AA, Stieglmaier J, Fey GH, Helfrich W: Superior
activity of fusion protein scFvRit:sFasL over cotreatment with rituximab
and Fas agonists. Cancer Res 2008, 68:597–604.
31. Chan DV, Sharma R, Ju C-Y A, Roffler SR, Ju S-T: A recombinant scFv-FasLext
as a targeting cytotoxic agent against human Jurkat-Ras cancer.
J Biomed Sci 2013, 20:16.
Muraki BMC Biotechnology 2014, 14:19 Page 16 of 16
http://www.biomedcentral.com/1472-6750/14/1932. Connolly K, Cho YH, Duan R, Fikes J, Gregorio T, Lafleuer DW, Okoye Z,
Salcedo TW, Santiago G, Ullrich S, Wei P, Windle K, Wong E, Yao XT, Zhang
YQ, Zheng G, Moore PA: In vivo inhibition of Fas ligand-mediated killing
by TR6, a Fas ligand decoy receptor. J Pharmcol Exp Therapeutics 2001,
298:25–33.
33. Linkermann A, Qian J, Lettau M, Kabelitz D, Janssen O: Considering Fas
ligand as a target for therapy. Expert Opin Ther Targets 2005, 9:119–134.
34. Lin WW, Hsieh SL: Decoy receptor 3: a pleiotropic immunomodulator and
biomarker for inflammatory diseases, autoimmune diseases and cancer.
Biochem Pharmacol 2011, 81:838–847.
35. Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R, Nishiyama T,
Takahashi K, Tomita Y: Prognostic impact of FAS/CD95/APO-1 in
urotherial cancers: decreased expression of Fas is associated with
disease progression. Brit J Cancer 2005, 93:544–551.
36. Kim Y, Ho SO, Gassman NR, Korlann Y, Landorf EV, Collart FR, Weiss S:
Efficient site-specific labeling of proteins via cysteines. Bioconj Chem
2008, 19:786–791.
37. Inouye S, Sato JI: Recombinant aequorin with a reactive cysteine residue
for conjugation with maleimide-activated antibody. Anal Biochem 2008,
378:105–107.
38. Boroumand-Noughabi S, Sima HR, Ghaffarzadehgan K, Jafarzadeh M, Raziee
HR, Hosseinnezhad H, Moaven O, Rajabi-Mashhabi MT, Azarian AA,
Mashhadinejad M, Tavakkol-Afshari J: Soluble Fas might serve as a
diagnostic tool for gastric adenocarcinoma. BMC Cancer 2010, 10:275.
39. Furuya Y, Nagakawa O, Fuse H: Prognostic significance of serum soluble
Fas level and its change during regression and progression of advanced
prostate cancer. Endocrine J 2003, 50:629–633.
40. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida
H, Hirao S, Mizuno T, Nakajima Y: The prognostic significance of
overexpression of the decoy receptor for Fas ligand (DcR3) in patients
with gastric carcinomas. Gastric Cancer 2002, 5:61–68.
41. Reimer T, Koczan D, Müller H, Friese K, Thiesen HJ, Gerber B: Tumor Fas
ligand: fas ratio greater than 1 is an independent marker of relative
resistance to tamoxifen therapy in hormone receptor positive breast
cancer. Breast Cancer Res 2002, 4:R9.
42. Tamakoshi A, Nakachi K, Ito Y, Lin Y, Yagyu K, Kikuchi S, Watanabe Y, Inaba
Y, Tajima K: Soluble Fas level and cancer mortality: findings from a
nested case-control study within a large-scale prospective study.
Int J Cancer 2008, 123:1913–1916.
doi:10.1186/1472-6750-14-19
Cite this article as: Muraki: Improved production of recombinant human
Fas ligand extracellular domain in Pichia pastoris: yield enhancement
using disposable culture-bag and its application to site-specific chemical
modifications. BMC Biotechnology 2014 14:19.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
